ArticleCell chemical biology2020
Overcoming Fungal Echinocandin Resistance through Inhibition of the Non-essential Stress Kinase Yck2.
Article in Cell chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 61 citations in OpenAlex.
- Lacticaseibacillus Paracasei Regulates Vaginal Microecology and Inhibits Hyphae Formation for Candida Vaginitis Therapy.Probiotics and antimicrobial proteins · 2026Article
- Article
- Structure-activity Relationship for Diarylpyrazoles as Inhibitors of the Fungal Kinase Yck2.bioRxiv : the preprint server for biology · 2025Article
- Chemoproteomic Profiling ofJournal of medicinal chemistry · 2025Article
- Synthesis of 2-Amino-4, 5-Diarylthiazole Derivatives and Evaluation of Their Anti-Molecules (Basel, Switzerland) · 2025Article
- Structure-guided optimization of small molecules targeting Yck2 as a strategy to combat Candida albicans.Nature communications · 2025Article
- Chemoproteomic Profiling ofbioRxiv : the preprint server for biology · 2025Article
- Structure-guided optimization of small molecules targeting the yeast casein kinase, Yck2, as a therapeutic strategy to combat Candida albicans.Research square · 2025Article
- Shape-Shifting Mechanisms: Integrative Multi-Omics Insights IntoMycobiology · 2025Review
- Evaluation of Fifteen 5,6-Dihydrotetrazolo[1,5-Journal of fungi (Basel, Switzerland) · 2024Article
- Interdisciplinary approaches for the discovery of novel antifungals.Trends in molecular medicine · 2024Review
- Brilacidin, a novel antifungal agent againstmBio · 2024Article
- The Ptk2-Pma1 pathway enhances tolerance to terbinafine inAntimicrobial agents and chemotherapy · 2024Article
- Advancements and challenges in antifungal therapeutic development.Clinical microbiology reviews · 2024Review
- Antifungal potential of marine bacterial compounds in inhibitingFrontiers in pharmacology · 2024Article
- Adaptation to an amoeba host drives selection of virulence-associated traits and genetic variation in saprotrophicFrontiers in cellular and infection microbiology · 2024Article
- Structural analogs of 2-(4-fluorophenyl)-6-methyl-3-(pyridin-4-yl)pyrazolo[1,5-a]pyridine for targetingFrontiers in chemistry · 2024Article
- An update on the global treatment of invasive fungal infections.Future microbiology · 2023Review
- Identification of triazenyl indoles as inhibitors of fungal fatty acid biosynthesis with broad-spectrum activity.Cell chemical biology · 2023Article
- Construction of Candida albicans Strains with ATP-Analog-Sensitive Protein Kinase A and Hog1.mSphere · 2023Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 3 countries.
Funding
Abstract
New strategies are urgently needed to counter the threat to human health posed by drug-resistant fungi. To explore an as-yet unexploited target space for antifungals, we screened a library of protein kinase inhibitors for the ability to reverse resistance of the most common human fungal pathogen, Candida albicans, to caspofungin, a widely used antifungal. This screen identified multiple 2,3-aryl-pyrazolopyridine scaffold compounds capable of restoring caspofungin sensitivity. Using chemical genomic, biochemical, and structural approaches, we established the target for our most potent compound as Yck2, a casein kinase 1 family member. Combination of this compound with caspofungin eradicated drug-resistant C. albicans infection while sparing co-cultured human cells. In mice, genetic depletion of YCK2 caused an ∼3-log
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.